Rakesh Jain - Tekla Healthcare Independent Trustees
THQ Fund | USD 20.30 0.47 2.37% |
Mr. Rakesh K. Jain, Ph.D. is Independent Trustees of Tekla Healthcare Opportunities Fund. Dr. Rakesh Jain is the Andrew Werk Cook Professor of Tumor Biology in the Department of Radiation Oncology at Harvard Medical School and the Director of the Edwin L. Steele Laboratory of Tumor Biology at Massachusetts General Hospital, providing each Fund with a valuable perspective on emerging life sciences technologies. Dr. Jain cofounded XTuit Pharmaceuticals, Inc. in 2011, where he also serves as a board member. He serves on the Governance and Nominating Committee of each Fund. Prior to joining Harvard, he was professor of chemical engineering at Columbia University and Carnegie Mellon University. Dr. Jain is regarded as a pioneer in the fields of tumor biology, drug delivery, in vivo imaging and bioengineering. Dr. Jain has authored more than 600 publications. He serves on advisory panels to government, industry and academia, and has served or continues to serve on editorial advisory boards of twenty journals, including Journal of Clinical Oncology and Nature Reviews Clinical Oncology. He has received more than 70 major awards and lectureships, including a Guggenheim Fellowship, the Humboldt Senior Scientist Award, the National Cancer Institute Research Career Development Award and Outstanding Investigator Grant, the Academic Scientist of the Year Award from the Pharmaceutical Achievements Awards, the Distinguished Service Award from Nature Biotechnology and the Innovator Award from the DoD Breast Cancer Program. He is a member of all three branches of US National Academies the Institute of Medicine, the National Academy of Engineering and the National Academy of Sciences and is a member of the American Academy of Arts and Sciences.
Age | 69 |
Tenure | 10 years |
Professional Marks | Ph.D |
Phone | 617 772 8500 |
Web | https://www.teklacap.com/thq.html |
Tekla Healthcare Management Performance (%)
Similar Money Managers
Showing other executives | One Year Return | ||
Helen Peters | Eaton Vance Tax | 73 | |
William Reardon | Tekla Healthcare Investors | 74 | |
Lisa Phelan | Cohen Steers Limited | 51 | |
William Cunningham | John Hancock Financial | 76 | |
Thomas Faust | Eaton Vance Tax | 63 | |
Peter Branner | Tekla Life Sciences | 60 | |
Laura Woodward | Tekla Healthcare Investors | 51 | |
Francis Knox | John Hancock Financial | 73 | |
William Reardon | Tekla World Healthcare | 74 | |
Lisa Phelan | Cohen Steers Qualityome | 52 | |
Lisa Phelan | Cohen Steers Reit | 51 | |
Lucinda Stebbins | Tekla Healthcare Investors | 73 | |
Theodore Uhl | Reaves Utility If | 45 | |
Frank Gentile | Tekla Healthcare Investors | 62 | |
James Kirchner | Eaton Vance Tax | 54 | |
Stacie Anctil | Pimco Corporate Income | 51 | |
Grace Fey | John Hancock Financial | 74 | |
Elizabeth Nabel | Tekla Healthcare Investors | 67 | |
Mary Anstine | Reaves Utility If | 79 | |
William Ogden | Pimco Corporate Income | 75 | |
Roger Ko | Flaherty Crumrine Total | 45 |
Tekla Healthcare Opp Leadership Team
Elected by the shareholders, the Tekla Healthcare's board of directors comprises two types of representatives: Tekla Healthcare inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Tekla. The board's role is to monitor Tekla Healthcare's management team and ensure that shareholders' interests are well served. Tekla Healthcare's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Tekla Healthcare's outside directors are responsible for providing unbiased perspectives on the board's policies.
Thomas Kent, Independent Trustee | ||
William Reardon, Independent Trustees | ||
Elizabeth Nabel, Independent Trustee | ||
Oleg Pohotsky, Independent Chairman of the Board of Trustees | ||
Laura Woodward, Chief Compliance Officer, Treasurer, Secretary | ||
Lucinda Stebbins, Independent Trustees | ||
Jeffrey Bailey, Independent Trustee | ||
Daniel Omstead, President, Trustee | ||
Rakesh Jain, Independent Trustees |
Tekla Fund Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right fund is not an easy task. Is Tekla Healthcare a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Shares Outstanding | 41.34 M | ||||
Shares Owned By Institutions | 19.54 % | ||||
Number Of Shares Shorted | 14.15 K | ||||
Price To Earning | 6.76 X | ||||
Short Ratio | 0.14 X | ||||
Earnings Per Share | 2.71 X | ||||
Beta | 0.9 | ||||
Market Capitalization | 951.66 M | ||||
Annual Yield | 0.01 % | ||||
Year To Date Return | 7.75 % |
Pair Trading with Tekla Healthcare
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Tekla Healthcare position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Tekla Healthcare will appreciate offsetting losses from the drop in the long position's value.Moving against Tekla Fund
0.52 | FTCAX | Templeton Strained Bond | PairCorr |
0.37 | PYARX | Payden Absolute Return | PairCorr |
0.37 | LTFOX | Lord Abbett Affiliated | PairCorr |
0.37 | GAB | Gabelli Equity Trust | PairCorr |
0.34 | PYAIX | Payden Absolute Return | PairCorr |
The ability to find closely correlated positions to Tekla Healthcare could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Tekla Healthcare when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Tekla Healthcare - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Tekla Healthcare Opportunities to buy it.
The correlation of Tekla Healthcare is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Tekla Healthcare moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Tekla Healthcare Opp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Tekla Healthcare can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Tekla Fund
Tekla Healthcare financial ratios help investors to determine whether Tekla Fund is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Tekla with respect to the benefits of owning Tekla Healthcare security.
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities |